Sadiqa Mahmood is the Senior Vice President and General Manager of the Life Sciences business at Health Catalyst and contributes to the overall vision and growth for the company. Sadiqa’s work focuses on identifying and addressing areas of high unmet need for therapeutic development through application of real-world data. She is an advisor to several healthcare organizations and global policy makers. Sadiqa is a dental surgeon and holds a master’s degree in public health from the Harvard School of Public Health.
Passionate about improving access to care and patient outcomes by leveraging data and healthcare ecosystem, Sadiqa has spent her career at the intersection of medicine, policy, technology, and analytics. Previously she led clinical analytics, quality and safety, value-based contracting, and population health across healthcare organizations, including the Dana-Farber Cancer Institute, Partners HealthCare System, and Boston Medical Center. Sadiqa has been an advocate of collaborative learning system in healthcare and has steered cross-industry multi-stakeholder national and global collaborations to drive healthcare innovation.
She joined Health Catalyst in 2019 as SVP of Medical Affairs. Sadiqa has lived and worked in Asia and UK in addition to the US. She is based in Boston, Massachusetts. Outside of work, she is a Formula 1 fan and race as a member of a local team.
(Analytics Best Practices, Innovative Data and Analytics Transformation, Machine Learning/AI — Course Level: Intermediate)
As COVID-19 makes timely access to comprehensive, accurate patient data increasingly urgent, healthcare organizations, pharma, and public health agencies are struggling to procure needed clinical information. An answer to this data challenge is a national data set that leverages deep, aggregated electronic health record data from patients across the United States, including patient history, comorbidities, vitals, treatment pathways, labs, and more. A proliferation of local standards and a lack of a standard COVID-19 definition has generated problems at the national level, driving the need for a standard COVID-19 patient type definition and registry. Only with this comprehensive, transparent view of patient health and the public health trends can providers, researchers, and policy makers make lasting, impactful progress against the outbreak. Discover how, with aggregated outbreak information from health systems across the United States, a standard COVID-19 definition and registry can accommodate the rapidly changing disease landscape and fill in critical gaps in clinical understanding.